TW270118B
(xx)
*
|
1993-02-26 |
1996-02-11 |
Schering Corp |
|
US5929046A
(en)
*
|
1994-06-08 |
1999-07-27 |
Cancer Research Campaign Technology Limited |
Pyrimidine and purine derivatives and their use in treating tumour cells
|
US5661153A
(en)
*
|
1994-07-19 |
1997-08-26 |
Japan Energy Corporation |
1-arylpyrimidine derivatives and pharmaceutical use thereof
|
AR004752A1
(es)
*
|
1995-11-28 |
1999-03-10 |
Schering Corp |
2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.
|
US5824683A
(en)
*
|
1995-11-28 |
1998-10-20 |
Schering Corporation |
2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
|
US5858694A
(en)
*
|
1997-05-30 |
1999-01-12 |
Cell Pathways, Inc. |
Method for identifying compounds for inhibition of cancerous lesions
|
CA2238283C
(en)
|
1997-05-30 |
2002-08-20 |
Cell Pathways, Inc. |
Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
|
US6410584B1
(en)
*
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
US6130053A
(en)
*
|
1999-08-03 |
2000-10-10 |
Cell Pathways, Inc. |
Method for selecting compounds for inhibition of neoplastic lesions
|
US6200771B1
(en)
|
1998-10-15 |
2001-03-13 |
Cell Pathways, Inc. |
Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
|
US6133271A
(en)
*
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
US6369092B1
(en)
|
1998-11-23 |
2002-04-09 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
US6034099A
(en)
*
|
1998-11-24 |
2000-03-07 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
US6077842A
(en)
*
|
1998-11-24 |
2000-06-20 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
|
US6025394A
(en)
|
1999-01-29 |
2000-02-15 |
Cell Pathways, Inc. |
Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
|
US6020379A
(en)
*
|
1999-02-19 |
2000-02-01 |
Cell Pathways, Inc. |
Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
|
US6555547B1
(en)
|
2000-02-28 |
2003-04-29 |
Cell Pathways, Inc. |
Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
|
US6569638B1
(en)
|
2000-03-03 |
2003-05-27 |
Cell Pathways, Inc |
Method for screening compounds for the treatment of neoplasia
|
US6821978B2
(en)
*
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
ES2302835T3
(es)
*
|
2001-08-28 |
2008-08-01 |
Schering Corporation |
Inhibidores de fosfodiesterasa v policiclicos de guanina.
|
EP1790652A1
(en)
*
|
2001-08-28 |
2007-05-30 |
Schering Corporation |
Polycyclic guanine phosphodiesterase V inhibitors
|
WO2003020702A2
(en)
|
2001-08-31 |
2003-03-13 |
The Rockefeller University |
Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
|
EP1312363A1
(en)
*
|
2001-09-28 |
2003-05-21 |
Pfizer Products Inc. |
Methods of treatment and kits comprising a growth hormone secretagogue
|
JP2005509038A
(ja)
|
2001-11-09 |
2005-04-07 |
シェーリング コーポレイション |
多環式グアニン誘導体ホスホジエステラーゼv阻害剤
|
US7342884B2
(en)
*
|
2002-03-13 |
2008-03-11 |
Harmonic, Inc. |
Method and apparatus for one directional communications in bidirectional communications channel
|
CN101538224A
(zh)
*
|
2002-05-31 |
2009-09-23 |
先灵公司 |
制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
|
EP1719772A1
(en)
|
2002-05-31 |
2006-11-08 |
Schering Corporation |
Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
|
ATE363483T1
(de)
*
|
2003-07-31 |
2007-06-15 |
Schering Corp |
Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
|
JP4377881B2
(ja)
*
|
2003-08-01 |
2009-12-02 |
日本曹達株式会社 |
フェニルアゾール化合物、製造法および抗酸化薬
|
BRPI0416202A
(pt)
*
|
2003-11-21 |
2006-12-26 |
Schering Corp |
formulações inibidoras de fosfodiesterase v
|
US20070004745A1
(en)
*
|
2005-03-25 |
2007-01-04 |
Schering-Plough Corporation |
Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
|
ES2645371T3
(es)
*
|
2005-06-06 |
2017-12-05 |
Intra-Cellular Therapies, Inc. |
Compuestos orgánicos
|
EP1919287A4
(en)
*
|
2005-08-23 |
2010-04-28 |
Intra Cellular Therapies Inc |
ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
|
KR101388688B1
(ko)
*
|
2005-11-09 |
2014-04-24 |
토소가부시키가이샤 |
퍼플루오로알킬기를 가진 핵산 염기 및 그 제조방법
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
US9255099B2
(en)
*
|
2006-06-06 |
2016-02-09 |
Intra-Cellular Therapies, Inc. |
Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
|
ES2411604T3
(es)
|
2006-11-13 |
2013-07-05 |
Intra-Cellular Therapies, Inc. |
Compuestos orgánicos
|
JP5837278B2
(ja)
*
|
2006-12-05 |
2015-12-24 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規使用
|
BRPI0812909A2
(pt)
*
|
2007-06-21 |
2014-12-09 |
Schering Corp |
Derivados de guanina policíclica e métodos de uso dos mesmos.
|
CN101969774A
(zh)
|
2007-12-06 |
2011-02-09 |
细胞内治疗公司 |
有机化合物
|
EP2939676A1
(en)
|
2007-12-06 |
2015-11-04 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
EP2358204B1
(en)
*
|
2008-12-06 |
2015-08-05 |
Intra-Cellular Therapies, Inc. |
4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors.
|
CN102223799A
(zh)
|
2008-12-06 |
2011-10-19 |
细胞内治疗公司 |
有机化合物
|
EA201170772A1
(ru)
|
2008-12-06 |
2012-03-30 |
Интра-Селлулар Терапиз, Инк. |
Органические соединения
|
US8536159B2
(en)
*
|
2008-12-06 |
2013-09-17 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
AU2009322903A1
(en)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
MX2011005935A
(es)
|
2008-12-06 |
2011-12-16 |
Intra Cellular Therapies Inc |
Compuestos organicos.
|
WO2010098839A1
(en)
|
2009-02-25 |
2010-09-02 |
Intra-Cellular Therapies, Inc. |
Pde 1 inhibitors for ophthalmic disorders
|
JP5765239B2
(ja)
*
|
2009-03-13 |
2015-08-19 |
アドヴィナス・セラピューティックス・リミテッド |
置換縮合ピリミジン化合物
|
US9468637B2
(en)
|
2009-05-13 |
2016-10-18 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
WO2011016861A2
(en)
|
2009-08-05 |
2011-02-10 |
Intra-Cellular Therapies, Inc. |
Novel regulatory proteins and inhibitors
|
WO2011081915A2
(en)
*
|
2009-12-15 |
2011-07-07 |
Cebix Inc. |
Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
|
JP5894148B2
(ja)
|
2010-05-31 |
2016-03-23 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
WO2011153138A1
(en)
|
2010-05-31 |
2011-12-08 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
EP2575817A4
(en)
|
2010-05-31 |
2014-01-08 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
TW201206937A
(en)
|
2010-05-31 |
2012-02-16 |
Intra Cellular Therapies Inc |
Organic compounds
|
JP6051210B2
(ja)
|
2011-06-10 |
2016-12-27 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
US9801882B2
(en)
|
2013-02-17 |
2017-10-31 |
Intra-Cellular Therapies, Inc. |
Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
|
EP2968338B1
(en)
|
2013-03-15 |
2019-01-09 |
Intra-Cellular Therapies, Inc. |
Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
|
CA2906640C
(en)
|
2013-03-15 |
2021-07-20 |
Intra-Cellular Therapies, Inc. |
Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors
|
EP3091983B1
(en)
|
2014-01-08 |
2019-10-02 |
Intra-Cellular Therapies, Inc. |
Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
|
DK3157926T3
(da)
|
2014-06-20 |
2019-08-19 |
Intra Cellular Therapies Inc |
Organiske forbindelser
|
US9546175B2
(en)
|
2014-08-07 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
WO2016022893A1
(en)
|
2014-08-07 |
2016-02-11 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
MX2017003646A
(es)
|
2014-09-17 |
2017-07-13 |
Intra Cellular Therapies Inc |
Compuestos y metodos.
|
CN107205993B
(zh)
|
2014-12-06 |
2021-03-09 |
细胞内治疗公司 |
有机化合物
|
WO2016090380A1
(en)
|
2014-12-06 |
2016-06-09 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
JP2019510039A
(ja)
|
2016-03-28 |
2019-04-11 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規組成物および方法
|
JP7134168B6
(ja)
|
2016-09-12 |
2024-02-02 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
EP3562828A1
(en)
|
2016-12-28 |
2019-11-06 |
Dart NeuroScience LLC |
Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
|
MX2020005447A
(es)
|
2017-11-27 |
2020-12-03 |
Dart Neuroscience Llc |
Compuestos de furanopirimidina sustituida como inhibidores de pde1.
|
EP3746081A4
(en)
|
2018-01-31 |
2021-10-27 |
Intra-Cellular Therapies, Inc. |
INNOVATIVE USES
|